保龄宝(002286) - 2019 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2019 was CNY 396,339,776.92, an increase of 2.45% compared to CNY 386,847,215.18 in the same period last year[7] - Net profit attributable to shareholders decreased by 28.14% to CNY 10,256,979.66 from CNY 14,273,392.27 year-on-year[7] - Net profit excluding non-recurring gains and losses fell by 43.28% to CNY 5,629,014.99 from CNY 9,924,466.48 in the previous year[7] - Net profit for Q1 2019 was CNY 10,256,632.74, a decrease of 27.5% from CNY 14,176,142.40 in Q1 2018[39] - The net profit for the current period is CNY 7,799,262.27, down 42.5% from CNY 13,564,404.80 in the previous period[43] - The total profit for the current period is CNY 8,927,279.49, a decrease of 43.5% compared to CNY 15,718,925.15 in the previous period[43] Cash Flow - Net cash flow from operating activities was negative at CNY -53,438,277.15, a decrease of 257.27% compared to CNY 33,978,190.86 in the same period last year[7] - The company's operating cash flow net amount is -CNY 53,438,277.15, compared to a positive CNY 33,978,190.86 in the previous period[47] - Cash and cash equivalents at the end of the period amount to CNY 115,587,878.65, down from CNY 172,475,829.74 at the end of the previous period[48] - The net cash flow from operating activities was -¥15,532,369.89, a decrease compared to ¥38,272,118.34 in the previous year[51] - The net cash flow from investing activities was -¥43,131,064.39, compared to ¥13,971,935.55 in the same period last year[51] - Total cash inflow from financing activities was ¥290,000,000.00, up from ¥151,200,000.00 year-over-year[52] Assets and Liabilities - Total assets increased by 4.98% to CNY 2,707,575,262.75 from CNY 2,579,253,042.83 at the end of the previous year[7] - As of March 31, 2019, the company's total assets amounted to CNY 2,707,575,262.75, an increase from CNY 2,579,253,042.83 at the end of 2018[29] - The company's total liabilities increased to CNY 1,157,461,511.65 from CNY 1,037,268,673.40, marking a rise of about 11.6%[30] - The company's total liabilities reached CNY 1,287,365,757.23, an increase from CNY 1,173,043,163.06 at the end of 2018, indicating a growth of 9.7%[35] - The total liabilities amounted to ¥1,037,268,673.40, consistent with the previous year's figures[55] - Total liabilities amounted to ¥1,173,043,163.06, with non-current liabilities at ¥50,270,001.27[58] Equity - The company's equity attributable to shareholders reached CNY 1,548,149,597.16, slightly up from CNY 1,540,019,868.57[31] - The total equity attributable to shareholders was ¥1,540,019,868.57, remaining stable compared to the prior year[55] - Total equity reached ¥1,506,890,879.13, including share capital of ¥369,256,000.00 and retained earnings of ¥288,310,238.88[58] Expenses - Management expenses rose by 56.66% year-on-year, mainly due to depreciation costs incurred during the Spring Festival holiday[17] - Asset impairment losses increased by 525.01% compared to the previous year, primarily due to an increase in bad debt provisions for other receivables[17] - Investment income decreased by 49.53% year-on-year, mainly due to reduced returns from bank wealth management products[17] - The company incurred financial expenses of CNY 7,720,725.44, an increase of 22.4% from CNY 6,308,987.08 in the previous period[42] - The company reported R&D expenses of CNY 822,685.66 for Q1 2019, an increase from CNY 648,715.52 in Q1 2018, reflecting a focus on innovation[37] - Research and development expenses for the current period are CNY 723,590.07, up from CNY 624,635.56 in the previous period[42] Other Notable Events - The company planned to acquire 11.37% of China Regenerative Medicine International Limited for HKD 360 million, equivalent to HKD 0.18 per share[19] - The company decided to terminate the acquisition of shares in China Regenerative Medicine due to the lack of necessary approvals[20] - The company did not report any non-compliance issues or overdue commitments during the reporting period[22] - The first quarter report was not audited, indicating a lack of external verification for the financial data presented[59]